LETTERS

Coronary Heart Disease Risk Factors and Mortality

To the Editor: Dr Canto and colleagues¹ found that hospital mortality increased as the number of cardiovascular risk factors declined. This inverse relationship is perplexing and the potential explanations discussed by the authors appear not completely satisfactory.

The authors just considered the number of risk factors, whereas the severity of each factor was not evaluated. Blood pressure, plasma glucose, and lipids are continuous, not discreet, variables that exert a dose-dependent effect on cardiovascular risk.² It would be of interest to see the results of the analysis conducted considering these parameters, which also would help to clarify the still controversial association of the metabolic syndrome and mortality after myocardial infarction (MI).³

It also would be interesting to know if the inverse correlation is still present after correction for one of the most important predictors of mortality after acute coronary syndrome,⁴ the baseline infarct size.

Last, traditional cardiovascular risk factors do not fully explain the pathophysiological process of atherothrombosis in acute ischemic heart disease. Several studies have identified a series of emerging biomarkers reflecting thrombosis, inflammation, and oxidative stress.⁵ Do the authors have any data about this issue?

Gaetano Santulli, MD

Author Affiliation: Columbia University Medical Center, New York, New York (gs2620@columbia.edu).

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest and none were reported.

1. Canto JG, Kiefe CI, Rogers WJ, et al; NRMI Investigators. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. *JAMA*. 2011;306(19):2120-2127.

2. D'Agostino RB Sr, Vasan RS, Pencina MJ, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. *Circulation*. 2008; 117(6):743-753.

3. Petersen JL, Yow E, AlJaroudi W, et al. Metabolic syndrome is not associated with increased mortality or cardiovascular risk in nondiabetic patients with a new diagnosis of coronary artery disease. *Circ Cardiovasc Qual Outcomes*. 2010; 3(2):165-172.

4. Wu E, Ortiz JT, Tejedor P, et al. Infarct size by contrast enhanced cardiac magnetic resonance is a stronger predictor of outcomes than left ventricular ejection fraction or end-systolic volume index: prospective cohort study. *Heart.* 2008; 94(6):730-736.

5. Wang TJ, Gona P, Larson MG, et al. Multiple biomarkers for the prediction of first major cardiovascular events and death. *N Engl J Med*. 2006;355(25):2631-2639.

To the Editor: The study by Dr Canto and colleagues¹ provides an example of an epidemiological phenomenon that deserves wider recognition. Differential selection from an underlying population cohort into a study data set can reverse the direction of observed associations, making a deleterious factor appear protective. It is well-known that conditioning on a variable that is affected by both an exposure and outcome can produce a distortion

known as selection bias.² Admission into the analysis data set in this study was a function of both the exposure (number of cardiovascular risk factors) and the outcome (all-cause, in-hospital, or 30-day mortality) because deaths occurring before hospitalization and patients with existing cardiovascular disease diagnoses were excluded. Approximately 30% of MIs lead to death prior to hospitalization.³ In the study, 75% of those who were admitted to the hospital after their MI were excluded (1.62 million of 2.16 million; Figure 1 in the article).

The combined effect of these 2 selection mechanisms means that individuals with more cardiovascular risk factors were more likely to be excluded. If an increased number of risk factors accelerate mortality so that more events occur in the prehospital window rather than during hospitalization or 30-day follow-up, risk factors will appear to be protective.⁴ The study results are therefore understandable in terms of selection bias and require no elaborate speculation about pathophysiological processes¹ or "novel but asyet uncharacterized and deadly CVD [cardiovascular disease] risk factors."⁵

Hailey R. Banack, MA Sam Harper, PhD Jay S. Kaufman, PhD

Author Affiliations: Department of Epidemiology, Biostatistics, and Occupational Health, McGill University, Toronto, Ontario, Canada (hailey.banack@mail.mcgill .ca).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMUE Form for Disclosure of Potential Conflicts of Interest. Dr Harper reported receiving a grant to his institution from Fonds de recherché du Québec-Santé. Dr Kaufman reported holding an endowed chair from the federal government of Canada. Ms Banack reported no disclosures.

1. Canto JG, Kiefe CI, Rogers WJ, et al; NRMI Investigators. Number of coronary heart disease risk factors and mortality in patients with first myocardial infarction. *JAMA*. 2011;306(19):2120-2127.

2. Hernán MA, Hernández-Díaz S, Robins JM. A structural approach to selection bias. *Epidemiology*. 2004;15(5):615-625.

3. Chambless L, Keil U, Dobson A, et al; WHO MONICA Project. Population versus clinical view of case fatality from acute coronary heart disease: results from the WHO MONICA Project 1985-1990. *Circulation*. 1997;96(11):3849-3859.

GUIDELINES FOR LETTERS. Letters discussing a recent JAMA article should be submitted within 4 weeks of the article's publication in print. Letters received after 4 weeks will rarely be considered. Letters should not exceed 400 words of text and 5 references and may have no more than 3 authors. Letters reporting original research should not exceed 600 words of text and 6 references and may have no more than 5 authors. They may include up to 2 tables or figures but online supplementary material is not allowed. All letters should include a word count. Letters must not duplicate other material published or submitted for publication. Letters not meeting these specifications are generally not considered. Letters will be published at the discretion of the editors and are subject to abridgement and editing. Further instructions can be found at http://jama.com/instructions. A signed statement for authorship criteria and responsibility, financial disclosure, copyright transfer, and acknowledgment and the ICMJE Form for Disclosure of Potential Conflicts of Interest are required before publication. Letters should be submitted via the JAMA online submission and review system at http://manuscripts.jama.com (note: do not include "www" before the URL). For technical assistance, please contact jama-letters@jama-archives.org.

Letters Section Editor: Jody W. Zylke, MD, Senior Editor.

©2012 American Medical Association. All rights reserved.

JAMA, March 21, 2012—Vol 307, No. 11 1137

LETTERS

	No. of Risk Factors at Presentation ^b					
	0	1	2	3	4	5
No. (%)						
MI (N = 630210)	83 978 (13.3)	195 238 (31.0)	205 224 (32.6)	111 384 (17.7)	30 893 (4.9)	3493 (0.6)
Crude hospital mortality	15 790 (18.8)	30 825 (15.8)	25 894 (12.6)	10 336 (9.3)	2293 (7.4)	220 (6.3)

^b Five major risk factors: smoking, diabetes, dyslipidemia, hypertension, and family history of coronary heart disease.

 Flanders WD, Klein M. Properties of 2 counterfactual effect definitions of a point exposure. *Epidemiology*. 2007;18(4):453-460.
Peterson ED, Gaziano JM. Cardiology in 2011—amazing opportunities, huge

 Peterson ED, Gaziano JM. Cardiology in 2011—amazing opportunities, huge challenges. JAMA. 2011;306(19):2158-2159.

In Reply: Our study challenges conventional wisdom that patients with more coronary heart disease (CHD) risk factors have worse outcomes following their first MI. We found that patients with multiple CHD risk factors presented much earlier in life with MI and had lower hospital mortality than patients with fewer or no risk factors. We confirmed that the high prevalence of risk factor exposure in patients with MI was consistent with the prior literature.

Dr Santulli seeks additional information that may enhance our study, such as the influence of a dose-dependent effect of CHD risk factors, presence of the metabolic syndrome, other novel risk markers, and infarct size. Unfortunately, these factors were not available in the National Registry of Myocardial Infarction. Although baseline infarct size was not recorded, the finding of an inverse relationship between the number of CHD risk factors and mortality was consistently observed among patients with low-, intermediate-, and high-risk features using 2 well-validated measures of infarct severity (Killip classification and TIMI Risk Index).

Ms Banack and colleagues suggest that bias in the selection of our study cohort could have reversed the direction of observed associations, making a deleterious factor appear protective. An MI cohort with no previous cardiovascular disease represents a more uniform population to study given the differences in management and treatment after atherosclerosis is manifest. Excluding patients with previous cardiovascular disease simply presents findings generalizable only to patients without previous disease. When our analysis was rerun using only an MI cohort with previous cardiovascular disease (N=630 210), our results did not change appreciably (TABLE).

Banack et al also raise the possibility that patients with multiple CHD risk factors might have died disproportionately before hospitalization. This is merely speculative. No prior study has examined the relationship between the number of CHD risk factors and mortality among patients with suspected MI who died prior to hospital arrival, perhaps due to the challenges of confirming MI in the prehospital setting. In the discussion of our findings, we devoted 4 paragraphs to methodological issues that may have limited generalizability and inferences of causality, including risk factor misclassification, bias with case ascertainment, residual confounding, healthy survivor bias, and index event bias.¹ Index event bias (also known as reverse epidemiology or collider stratification bias) may affect research that examines disease progression and severity when there are multiple risk factors for progression or for severity that are also risk factors for having the disease in the first place.¹ We also present biologically plausible alternative interpretations of our findings, including receipt of more aggressive treatments and follow-up care among patients with multiple CHD risk factors.

In summary, we report an unexpected and possibly controversial association that, like all observational findings, should be considered hypothesis-generating and further explored in terms of health care provided to patients who reach the hospital alive with first MI.

John G. Canto, MD, MSPH Catarina I. Kiefe, MD, PhD Philip Greenland, MD

Author Affiliations: Center for Cardiovascular Prevention, Research and Education, Watson Clinic LLP, Lakeland, Florida (Dr Canto) (jcanto@watsonclinic.com); Department of Quantitative Health Sciences, University of Massachusetts Medical School, Worcester (Dr Kiefe); and Clinical and Translational Sciences Institute, Northwestern University, Chicago, Illinois (Dr Greenland).

Conflict of Interest Disclosures: The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Drs Kiefe and Greenland reported receiving grants from the National Institutes of Health. Dr Greenland also reported being a consultant to the University of Pennsylvania, Ohio State University, and the National Heart, Lung, and Blood Institute; and receiving payment for lectures from the National Institutes of Health and several universities. Dr Canto reported no disclosures.

1. Dahabreh IJ, Kent DM. Index event bias as an explanation for the paradoxes of recurrence risk research. JAMA. 2011;305(8):822-823.

Urinary Sodium Excretion and Cardiovascular Events

To the Editor: Dr O'Donnell and colleagues, in their study on urinary sodium excretion and risk of cardiovascular events,¹ reached the counterintuitive conclusion that sodium restriction increased the risk of cardiovascular events, which runs counter to the consistent evidence that, in individuals with hypertension, decreased sodium intake reduces blood pressure and improves the effectiveness of treatment with antihypertensive agents.²⁻⁴

1138 JAMA, March 21, 2012-Vol 307, No. 11

©2012 American Medical Association. All rights reserved.